Gill Lab

Recent Publications

  1. Kenderian SS, Ruella M, Gill S, Kalos M. Chimeric Antigen Receptor T-cell Therapy to Target Hematologic Malignancies. Cancer Res. 2014  Nov  15;74(22):6383-6389. Epub 2014 Nov 4. Review. PubMed PMID: 25371415.
  2. Reshef R, Hexner EO, Loren AW, Frey NV, Stadtmauer EA, Luger SM, Mangan JK, Gill SI, Vassilev P, Lafferty KA, Smith J, Van Deerlin VM, Mick R, Porter DL. Early donor chimerism levels predict relapse and survival after allogeneic stem cell transplantation with reduced-intensity conditioning. Biol Blood Marrow Transplant. 2014 Nov;20(11):1758-66. doi: 10.1016/j.bbmt.2014.07.003. Epub 2014 Jul 10. PubMed PMID:  25016197; PubMed Central PMCID: PMC4194246.
  3. Gill S, Tasian SK, Ruella M, Shestova O, Li Y, Porter DL, Carroll M, Danet-Desnoyers G, Scholler J, Grupp SA, June CH, Kalos M. Preclinical  targeting  of human acute myeloid leukemia and myeloablation using chimeric antigen receptor-modified T cells. Blood. 2014 Apr  10;123(15):2343-54. doi:10.1182/blood-2013-09-529537. Epub 2014 Mar 4. PubMed PMID: 24596416; PubMed Central PMCID: PMC3983612.
  4. Gill S, Porter DL. CAR-modified anti-CD19 T cells for the treatment of B-cell malignancies: rules of the road. Expert Opin Biol Ther. 2014  Jan;14(1):37-49.doi: 10.1517/14712598.2014.860442. Epub 2013 Nov 21. Review. PubMed PMID:24261468.
  5. Ganetsky A, Kucharczuk C, Del Percio S, Frey N, Gill S. Spontaneous subcapsular splenic hematoma associated with filgrastim in a patient undergoing allogeneic hematopoietic stem cell transplantation. Ann Pharmacother. 2013 May;47(5):e22. doi: 10.1345/aph.1S005. Epub 2013 Apr 12. PubMed PMID: 23585644.
  6. Gill S, Kalos M. T cell-based gene therapy of cancer. Transl Res. 2013 Apr;161(4):365-79. doi: 10.1016/j.trsl.2012.11.002. Epub 2012 Dec 11. Review. PubMed PMID: 23246626.
  7. Gill S, Porter DL. Reduced-intensity hematopoietic stem cell transplants for malignancies: harnessing the graft-versus-tumor effect. Annu  Rev Med. 2013;64:101-17. doi: 10.1146/annurev-med-121411-103452. Epub 2012 Oct 29. Review. PubMed PMID: 23121181.
  8. Gill S, Vasey AE, De Souza A, Baker J, Smith AT, Kohrt HE, Florek M, Gibbs KD  Jr, Tate K, Ritchie DS, Negrin RS. Rapid development of  exhaustion and down-regulation of eomesodermin limit the antitumor activity of adoptively transferred murine natural killer cells. Blood. 2012 Jun 14;119(24):5758-68. doi:10.1182/blood-2012-03-415364. Epub 2012 Apr 27. PubMed PMID: 22544698; PubMed Central PMCID: PMC3382935.
  9. Chao MP, Alizadeh AA, Tang C, Myklebust JH, Varghese B, Gill S, Jan M, Cha AC, Chan CK, Tan BT, Park CY, Zhao F, Kohrt HE, Malumbres R, Briones J, Gascoyne RD, Lossos IS, Levy R, Weissman IL, Majeti R. Anti-CD47 antibody synergizes with rituximab to promote phagocytosis and eradicate non-Hodgkin lymphoma. Cell. 2010 Sep 3;142(5):699-713. doi: 10.1016/j.cell.2010.07.044. PubMed PMID: 20813259; PubMed Central PMCID: PMC2943345.
  10. Olson JA, Leveson-Gower DB, Gill S, Baker J, Beilhack A, Negrin RS. NK cells  mediate reduction of GVHD by inhibiting activated, alloreactive T cells while retaining GVT effects. Blood. 2010 May 27;115(21):4293-301. doi:10.1182/blood-2009-05-222190. Epub 2010 Mar 16. PubMed PMID: 20233969; PubMed Central PMCID: PMC2879101.
  11. Benjamin JE, Gill S, Negrin RS. Biology and clinical effects of natural killer cells in allogeneic transplantation. Curr Opin Oncol. 2010 Mar;22(2):130-7. doi: 10.1097/CCO.0b013e328335a559. Review. PubMed PMID:20010294; PubMed Central PMCID: PMC2880497.
  12. Gill S, Herbert KE, Prince HM, Wolf MM, Wirth A, Ryan G, Carney DA, Ritchie DS, Davies JM, Seymour JF. Mantle cell lymphoma with central nervous  System involvement: frequency and clinical features. Br J Haematol. 2009 Oct;147(1):83-8. doi: 10.1111/j.1365-2141.2009.07835.x. Epub 2009 Aug 19. PubMed PMID: 19694718.
  13. Gill S, Olson JA, Negrin RS. Natural killer cells in allogeneic transplantation: effect on engraftment, graft- versus-tumor, and graft-versus-host responses. Biol Blood Marrow Transplant. 2009 Jul;15(7):765-76.doi: 10.1016/j.bbmt.2009.01.019. Epub 2009 Apr 2. Review. PubMed PMID: 19539207; PubMed Central PMCID: PMC2884143.
  14. Gill S, Seymour JF. What is the real risk of central nervous system involvement in mantle cell lymphoma? Leuk Lymphoma. 2008 Dec;49(12):2237-9. doi: 10.1080/10428190802495855. PubMed PMID: 19052969.
  15. Gill S, Hicks RJ, Seymour JF. What is the role of 18F-fluorodeoxyglucose positron emission tomography in mantle cell lymphoma? Leuk Lymphoma. 2008 Sep;49(9):1653-6. doi: 10.1080/10428190802311433. Review. PubMed PMID: 18798097.
  16. Gill S, Wolf M, Prince HM, Januszewicz H, Ritchie D, Hicks RJ, Seymour JF. [18F]fluorodeoxyglucose positron emission tomography scanning for staging, response assessment, and disease surveillance in patients with mantle cell lymphoma. Clin Lymphoma Myeloma. 2008 Jun;8(3):159-65. doi:10.3816/CLM.2008.n.019. PubMed PMID: 18650179.
  17. Gill S, Lane SW, Crawford J, Cull G, Joske D, Marlton P, Mollee PN, Prince HM, Seymour JF. Prolonged haematological toxicity from the hyper-CVAD regimen: manifestations, frequency, and natural history in a cohort of 125 consecutive patients. Ann Hematol. 2008 Sep;87(9):727-34. doi: 10.1007/s00277-008-0488-6. Epub 2008 Apr 10. PubMed PMID: 18401583.
  18. Gill S, Ritchie D. Therapeutic options in mantle cell lymphoma. Leuk Lymphoma. 2008 Mar;49(3):398-409. doi: 10.1080/10428190701851364. Review. PubMed PMID: 18297516.
  19. Gill S, Shapiro J, Westerman D, Prince HM. Long-term survival and secondary acute leukemia after fotemustine therapy for metastatic melanoma. J Clin Oncol. 2007 Oct 1;25(28):4493-4. PubMed PMID: 17906211.